View in EDS HTML Full Text PDF Full Text

SEMA3B is associated with disease activity and infliximab response in IBD patients but does not contribute to the development of intestinal inflammation in vivo.

Saved in:
Bibliographic Details
Title: SEMA3B is associated with disease activity and infliximab response in IBD patients but does not contribute to the development of intestinal inflammation in vivo.
Authors: Arosa L; Molecular and Cellular Gastroenterology Group, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain., Malvar-Fernández B; Rheumatology & Immuno-mediated Diseases Research Group (IRIDIS), Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Vigo, Spain.; Rheumatology Department, University Hospital of Vigo, Vigo, Spain., Antúnez-López J; Department of Pathology, University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain., García S; Rheumatology & Immuno-mediated Diseases Research Group (IRIDIS), Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Vigo, Spain.; Rheumatology Department, University Hospital of Vigo, Vigo, Spain., Conde-Aranda J; Molecular and Cellular Gastroenterology Group, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
Source: Frontiers in immunology [Front Immunol] 2026 Feb 04; Vol. 17, pp. 1677130. Date of Electronic Publication: 2026 Feb 04 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41716378
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: SEMA3B is associated with disease activity and infliximab response in IBD patients but does not contribute to the development of intestinal inflammation in vivo.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Arosa+L%22">Arosa L</searchLink>; Molecular and Cellular Gastroenterology Group, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.<br /><searchLink fieldCode="AU" term="%22Malvar-Fernández+B%22">Malvar-Fernández B</searchLink>; Rheumatology & Immuno-mediated Diseases Research Group (IRIDIS), Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Vigo, Spain.; Rheumatology Department, University Hospital of Vigo, Vigo, Spain.<br /><searchLink fieldCode="AU" term="%22Antúnez-López+J%22">Antúnez-López J</searchLink>; Department of Pathology, University Clinical Hospital of Santiago de Compostela, Santiago de Compostela, Spain.<br /><searchLink fieldCode="AU" term="%22García+S%22">García S</searchLink>; Rheumatology & Immuno-mediated Diseases Research Group (IRIDIS), Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Vigo, Spain.; Rheumatology Department, University Hospital of Vigo, Vigo, Spain.<br /><searchLink fieldCode="AU" term="%22Conde-Aranda+J%22">Conde-Aranda J</searchLink>; Molecular and Cellular Gastroenterology Group, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101560960%22">Frontiers in immunology</searchLink> [Front Immunol] 2026 Feb 04; Vol. 17, pp. 1677130. <i>Date of Electronic Publication: </i>2026 Feb 04 (<i>Print Publication: </i>2026).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101560960 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1664-3224 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216643224%22">16643224 </searchLink><i>NLM ISO Abbreviation: </i>Front Immunol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41716378
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fimmu.2026.1677130
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1677130
    Titles:
      – TitleFull: SEMA3B is associated with disease activity and infliximab response in IBD patients but does not contribute to the development of intestinal inflammation in vivo.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Arosa L
      – PersonEntity:
          Name:
            NameFull: Malvar-Fernández B
      – PersonEntity:
          Name:
            NameFull: Antúnez-López J
      – PersonEntity:
          Name:
            NameFull: García S
      – PersonEntity:
          Name:
            NameFull: Conde-Aranda J
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 04
              M: 02
              Text: 2026 Feb 04
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1664-3224
          Numbering:
            – Type: volume
              Value: 17
          Titles:
            – TitleFull: Frontiers in immunology
              Type: main
ResultId 1